« Return to News | Clinical Intelligence

Top Stories for the Week of April 30th 2007

Monday, April 30, 2007 02:12 PM

Top News

Western IRB Sells Majority Stake to Boston Ventures

Private equity firm Boston Ventures has bought a majority stake in Western IRB (WIRB), a Seattle, Wash.-based independent review board (IRB). Financial terms were not disclosed. IRBs review research sponsored by organizations such as academic institutions and pharmaceutical companies. WIRB is one the largest IRBs worldwide. The company has about 300 employees and works in 34 countries.

PHT Taps Japanese Marketplace with Mebix Partnership

Charlestown, Mass.-based electronic patient reported outcomes (ePRO) company PHT has entered into a partnership with Mebix, a data management and evidence-based medicine monitoring solutions company based in Japan. Mebix will provide PHT with sales support, project management and study monitoring at the local level. PHT already has four trial projects through the Mebix partnership.

Other breaking news...  

Company Profile: An interview with Venkatraman Sunder, vice president, Operations, Asian Clinical Trials

To read the full articles for this issue or for more information on these and other breaking stories, pleaseclick herefor subscription information.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.